1. Home
  2. OOMA vs LRMR Comparison

OOMA vs LRMR Comparison

Compare OOMA & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ooma Inc.

OOMA

Ooma Inc.

HOLD

Current Price

$17.75

Market Cap

408.2M

Sector

Technology

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$3.96

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OOMA
LRMR
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
408.2M
455.8M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
OOMA
LRMR
Price
$17.75
$3.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$18.77
$16.50
AVG Volume (30 Days)
220.1K
1.3M
Earning Date
05-27-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
188.46
N/A
EPS
0.23
N/A
Revenue
$114,490,000.00
N/A
Revenue This Year
$20.35
N/A
Revenue Next Year
$4.17
$1,816.14
P/E Ratio
$71.00
N/A
Revenue Growth
9.53
N/A
52 Week Low
$9.79
$1.73
52 Week High
$16.89
$6.42

Technical Indicators

Market Signals
Indicator
OOMA
LRMR
Relative Strength Index (RSI) 80.02 31.12
Support Level $10.95 $3.87
Resistance Level N/A $4.18
Average True Range (ATR) 0.56 0.21
MACD 0.14 -0.09
Stochastic Oscillator 98.71 6.31

Price Performance

Historical Comparison
OOMA
LRMR

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: